MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab

British Journal of Haematology

Volumn 165, Issue 3, 2014, Pages 382-391

  Perry, Anamarija M ^a   Alvarado Bernal, Yuridia ^b   Laurini, Javier A ^c   Smith, Lynette M ^d   Slack, Graham W ^e   Tan, King L ^e   Sehn, Laurie H ^e   Fu, Kai ^f   Aoun, Patricia ^g   Greiner, Timothy C ^f   Chan, Wing C ^f   Bierman, Philip J ^f   Bociek, Robert G ^f   Armitage, James O ^f   Vose, Julie M ^f   Gascoyne, Randy D ^e   Weisenburger, Dennis D ^g  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^c UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aggressive lymphoma; BCL2; Diffuse large B cell lymphoma; Double hit lymphoma; MYC

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; KI 67 ANTIGEN; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; EVENT FREE SURVIVAL; FEMALE; GERMINAL CENTER; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL PREDICTION;

AGGRESSIVE LYMPHOMA; BCL2; DIFFUSE LARGE B-CELL LYMPHOMA; DOUBLE-HIT LYMPHOMA; MYC;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84898462636     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12763     Document Type: Article

References (41)

1. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, J. Jr, Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. & Staudt, L.M. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-511.
2. Aukema, S.M., Siebert, R., Schuuring, E., van Imhoff, G.W., Kluin-Nelemans, H.C., Boerma, E.J. & Kluin, P.M. (2011) Double-hit B-cell lymphomas. Blood, 117, 2319-2331.
3. Barrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Patmore, R., Roman, E. & Jack, A. (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. Journal of Clinical, 28, 3360-3365.
4. Broyde, A., Boycov, O., Strenov, Y., Okon, E., Shpilberg, O. & Bairey, O. (2009) Role and prognostic significance of the ki-67 index in non-hodgkin's lymphoma. American Journal of Hematology, 84, 338-343.
5. Choi, W.W., Weisenburger, D.D., Greiner, T.C., Piris, M.A., Banham, A.H., Delabie, J., Braziel, R.M., Geng, H., Iqbal, J., Lenz, G., Vose, J.M., Hans, C.P., Fu, K., Smith, L.M., Li, M., Liu, Z., Gascoyne, R.D., Rosenwald, A., Ott, G., Rimsza, L.M., Campo, E., Jaffe, E.S., Jaye, D.L., Staudt, L.M. & Chan, W.C. (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clinical Cancer Research, 15, 5494-5502.
6. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346, 235-242.
7. Crowley, J. (Ed). (2001) Prognostic factor studies. In: Statistics in Oncology. pp. 321-378. Marcel Dekker, New York, NY.
8. Fu, K., Weisenburger, D.D., Choi, W.W., Perry, K.D., Smith, L.M., Shi, X., Hans, C.P., Greiner, T.C., Bierman, P.J., Bociek, R.G., Armitage, J.O., Chan, W.C. & Vose, J.M. (2008) Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Journal of Clinical Oncology, 26, 4587-4594.
9. Green, T.M., Nielsen, O., de Stricker, K., Xu-Monette, Z.Y., Young, K.H. & Moller, M.B. (2012a) High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. The American Journal of Surgical Pathology, 36, 612-619.
10. Green, T.M., Young, K.H., Visco, C., Xu-Monette, Z.Y., Orazi, A., Go, R.S., Nielsen, O., Gadeberg, O.V., Mourits-Andersen, T., Frederiksen, M., Pedersen, L.M. & Moller, M.B. (2012b) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3460-3467.
11. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
12. Horn, H., Ziepert, M., Becher, C., Barth, T.F., Bernd, H.W., Feller, A.C., Klapper, W., Hummel, M., Stein, H., Hansmann, M.L., Schmelter, C., Moller, P., Cogliatti, S., Pfreundschuh, M., Schmitz, N., Trumper, L., Siebert, R., Loeffler, M., Rosenwald, A. & Ott, G. & German High-Grade Non-Hodgkin Lymphoma Study Group. (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood, 121, 2253-2263.
13. Hothorn, T., Hornik, K. & Zeileis, A. (2006) Unbiased recursive partitioning: a conditional inference framework. Journal of Computational and Graphical Statistics, 15, 651-674.
14. Hu, S., Xu-Monette, Z.Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A., Liu, W.M., Visco, C., Li, Y., Miranda, R.N., Montes-Moreno, S., Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Richards, K.L., Hsi, E.D., Choi, W.W., Zhao, X., van Krieken, J.H., Huang, Q., Huh, J., Ai, W., Ponzoni, M., Ferreri, A.J., Zhou, F., Slack, G.W., Gascoyne, R.D., Tu, M., Variakojis, D., Chen, W., Go, R.S., Piris, M.A., Moller, M.B., Medeiros, L.J. & Young, K.H. (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from the international DLBCL rituximab-CHOP consortium program. Blood, 121, 4021-4031.
15. Huang, J.Z., Sanger, W.G., Greiner, T.C., Staudt, L.M., Weisenburger, D.D., Pickering, D.L., Lynch, J.C., Armitage, J.O., Warnke, R.A., Alizadeh, A.A., Lossos, I.S., Levy, R. & Chan, W.C. (2002) The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood, 99, 2285-2290.
16. International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The New England Journal of Medicine, 329, 987-994.
17. Iqbal, J., Meyer, P.N., Smith, L.M., Johnson, N.A., Vose, J.M., Greiner, T.C., Connors, J.M., Staudt, L.M., Rimsza, L., Jaffe, E., Rosenwald, A., Ott, G., Delabie, J., Campo, E., Braziel, R.M., Cook, J.R., Tubbs, R.R., Gascoyne, R.D., Armitage, J.O., Weisenburger, D.D. & Chan, W.C. (2011) BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clinical Cancer Research, 17, 7785-7795.
18. Johnson, N.A., Savage, K.J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M.J., Siebert, R., Kuruvilla, J., Klasa, R., Connors, J.M., Gascoyne, R.D. & Horsman, D.E. (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood, 114, 2273-2279.
19. Johnson, N.A., Slack, G.W., Savage, K.J., Connors, J.M., Ben-Neriah, S., Rogic, S., Scott, D.W., Tan, K.L., Steidl, C., Sehn, L.H., Chan, W.C., Iqbal, J., Meyer, P.N., Lenz, G., Wright, G., Rimsza, L.M., Valentino, C., Brunhoeber, P., Grogan, T.M., Braziel, R.M., Cook, J.R., Tubbs, R.R., Weisenburger, D.D., Campo, E., Rosenwald, A., Ott, G., Delabie, J., Holcroft, C., Jaffe, E.S., Staudt, L.M. & Gascoyne, R.D. (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3452-3459.
20. Klapper, W., Stoecklein, H., Zeynalova, S., Ott, G., Kosari, F., Rosenwald, A., Loeffler, M., Trumper, L., Pfreundschuh, M. & Siebert, R. & German High-Grade Non-Hodgkin's Lymphoma Study Group. (2008) Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the german high-grade non-hodgkin's lymphoma study group (DSHNHL). Leukemia, 22, 2226-2229.
21. Kluk, M.J., Chapuy, B., Sinha, P., Roy, A., Dal Cin, P., Neuberg, D.S., Monti, S., Pinkus, G.S., Shipp, M.A. & Rodig, S.J. (2012) Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS ONE, 7, e33813.
22. Kremers, W.K. (Ed) (2007) Concordance for Survival Time Data: Fixed and Time-Dependent Covariates and Possible Ties in Predictor and Time. Technical Report Series No. 80. Mayo Clinic, Rochester, MN.
23. Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C. & Staudt, L.M. & Lymphoma/Leukemia Molecular Profiling Project. (2008) Stromal gene signatures in large-B-cell lymphomas. The New England Journal of Medicine, 359, 2313-2323.
24. Li, S., Lin, P., Fayad, L.E., Lennon, P.A., Miranda, R.N., Yin, C.C., Lin, E. & Medeiros, L.J. (2012) B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Modern Pathology, 25, 145-156.
25. Meyer, P.N., Fu, K., Greiner, T.C., Smith, L.M., Delabie, J., Gascoyne, R.D., Ott, G., Rosenwald, A., Braziel, R.M., Campo, E., Vose, J.M., Lenz, G., Staudt, L.M., Chan, W.C. & Weisenburger, D.D. (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. Journal of Clinical Oncology, 29, 200-207.
26. Mounier, N., Briere, J., Gisselbrecht, C., Emile, J.F., Lederlin, P., Sebban, C., Berger, F., Bosly, A., Morel, P., Tilly, H., Bouabdallah, R., Reyes, F., Gaulard, P. & Coiffier, B. (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood, 101, 4279-4284.
27. R Development Core Team. (2009) R: A language and environment for statistical computing. In: R Foundation for Statistical Computing. R Development Core Team, Vienna. ISBN 3-900051-07-0, Available at: http://www.R-project.org [Accessed September 30, 2011].
28. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. & Staudt, L.M. & Lymphoma/Leukemia Molecular Profiling Project. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346, 1937-1947.
29. Salles, G., de Jong, D., Xie, W., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W., Calaminici, M., Sander, B., Thorns, C., Campo, E., Molina, T., Lee, A., Pfreundschuh, M., Horning, S., Lister, A., Sehn, L.H., Raemaekers, J., Hagenbeek, A., Gascoyne, R.D. & Weller, E. (2011) Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the lunenburg lymphoma biomarker consortium. Blood, 117, 7070-7078.
30. Savage, K.J., Johnson, N.A., Ben-Neriah, S., Connors, J.M., Sehn, L.H., Farinha, P., Horsman, D.E. & Gascoyne, R.D. (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood, 114, 3533-3537.
31. Sehn, L.H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J.J., Sutherland, J., Wilson, K.S., Gascoyne, R.D. & Connors, J.M. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in british columbia. Journal of Clinical Oncology, 23, 5027-5033.
32. Slack, G.W. & Gascoyne, R.D. (2011) MYC and aggressive B-cell lymphomas. Advances in Anatomic Pathology, 18, 219-228.
33. Snuderl, M., Kolman, O.K., Chen, Y.B., Hsu, J.J., Ackerman, A.M., Dal Cin, P., Ferry, J.A., Harris, N.L., Hasserjian, R.P., Zukerberg, L.R., Abramson, J.S., Hochberg, E.P., Lee, H., Lee, A.I., Toomey, C.E. & Sohani, A.R. (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from burkitt lymphoma and diffuse large B-cell lymphoma. The American Journal of Surgical Pathology, 34, 327-340.
34. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (Eds) (2008) Diffuse large B-cell lymphoma, not otherwise specified. In: World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, pp. 233-237. IARC Press, Lyon.
35. Tzankov, A., Zlobec, I., Went, P., Robl, H., Hoeller, S. & Dirnhofer, S. (2010) Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leukemia & Lymphoma, 51, 199-212.
36. Valera, A., Lopez-Guillermo, A., Cardesa-Salzmann, T., Climent, F., Gonzalez-Barca, E., Mercadal, S., Espinosa, I., Novelli, S., Briones, J., Mate, J.L., Salamero, O., Sancho, J.M., Arenillas, L., Serrano, S., Erill, N., Martinez, D., Castillo, P., Rovira, J., Martinez, A., Campo, E., Colomo, L. & Grup per l'Estudi dels Limfomes de Catalunya i Balears (GELCAB)(2013) MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica, 98, 1554-1562.
37. Visco, C., Tzankov, A., Xu-Monette, Z.Y., Miranda, R.N., Tai, Y.C., Li, Y., Liu, W.M., d'Amore, E.S., Li, Y., Montes-Moreno, S., Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Wang, H.Y., Dunphy, C.H., His, E.D., Zhao, X.F., Choi, W.W., Zhao, X., van Krieken, J.H., Huang, Q., Ai, W., O'Neill, S., Ponzoni, M., Ferreri, A.J., Kahl, B.S., Winter, J.N., Go, R.S., Dirnhofer, S., Piris, M.A., Moller, M.B., Wu, L., Medeiros, L.J. & Young, K.H. (2013) Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an international DLBCL rituximab-CHOP consortium program study. Haematologica, 98, 255-263.
38. Wilson, K.S., Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C.A., Gill, K.K., Klasa, R., Skinnider, B., Sutherland, J., Connors, J.M. & Gascoyne, R.D. (2007) CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leukemia & Lymphoma, 48, 1102-1109.
39. Wright, G., Tan, B., Rosenwald, A., Hurt, E.H., Wiestner, A. & Staudt, L.M. (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 100, 9991-9996.
40. Yoon, S.O., Jeon, Y.K., Paik, J.H., Kim, W.Y., Kim, Y.A., Kim, J.E. & Kim, C.W. (2008) MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology, 53, 205-217.
41. Yoon, D.H., Choi, D.R., Ahn, H.J., Kim, S., Lee, D.H., Kim, S.W., Park, B.H., Yoon, S.O., Huh, J., Lee, S.W. & Suh, C. (2010) Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. European Journal of Haematology, 85, 149-157.